The Medical Research Council has invested £50 million into a new centre of research excellence focused on mitochondrial diseases, in a move aimed at improving understanding of a group of genetic disorders that currently have no cure. The announcement, published on 5 August 2026, places the United Kingdom at the centre of a long-term effort to translate basic science into new therapies for patients and families affected by these conditions.
The new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics brings together experts across disciplines to define how mutations in mitochondrial DNA cause disease and then convert that knowledge into treatment strategies. According to the MRC, mitochondrial diseases affect around one in 5,000 people and can lead to significant unmet medical needs, progressive decline and premature death. The council also notes that mutations in mitochondrial DNA are increasingly linked to neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration.
A UK-led platform for therapies targeting mtDNA mutations
Project lead Professor Michal Minczuk of the University of Cambridge said the centre will provide approaches to understanding and treating diseases caused by mutations in the mitochondrial genome. He said the aim is to build a long-term UK research platform with the scale, expertise and infrastructure needed to position the country as a global leader in mitochondrial genome therapeutics. The project is designed to create the scientific foundations for entirely new therapeutic strategies and renewed hope for patients and families.
The centre will harness emerging technologies to engineer the mitochondrial genome and create advanced models of pathogenic mtDNA mutations. It is being led by the University of Cambridge and will partner with the University of Birmingham, The University of Manchester, Heidelberg University, University of Queensland and the Imagine Institute in Paris. The MRC says the initiative will also work with charities, including the Lily Foundation, and with industry partners worldwide.
Why the research matters for patients
Dr Ceri Williams, Executive Director of Challenge Led Themes at MRC, said the UK has long played a leading role in mitochondrial science, including the development of mitochondrial replacement therapy that prevents the inheritance of mtDNA mutations. She said the new centre builds on those foundations and that an interdisciplinary approach could transform health research in the field by improving prevention, detection and treatment while boosting outcomes for patients.
Patient charity partner the Lily Foundation said it will help ensure that family priorities shape the research from the outset. Chief Executive Officer Liz Curtis said the programme reflects the kind of strategic, collaborative work the charity wants to support, including investment in the next generation of scientists. For clinicians and researchers, the new funding signals a sustained push to turn mitochondrial biology into tangible clinical progress.
With no current cure and a wide range of severe consequences associated with mitochondrial disease, the new MRC investment marks one of the most significant UK commitments to this area in recent years. The next phase will be to see whether the combined expertise of the research partners can speed the path from genetic insight to practical treatment options.
